GU Cancers 2024 | The potential role of TIGIT/LAG-3 inhibition in urothelial carcinoma

Girish Kulkarni, MD, PhD, University of Toronto, Ontario, Canada, comments on the possible role of TIGIT/LAG-3 inhibition in the treatment landscape of urothelial carcinoma. Whilst checkpoint inhibitors are associated with adverse events such as myocarditis, neurodegenerative disorders and colitis, more research is needed if these inhibitors will have a synergistic effect with other immunotherapies. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.